Active Filter(s):
Details:
Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name Romet™ for the treatment of asthma. Romet™ was marketed for over 25 years in Japan.
Lead Product(s): Repirinast
Therapeutic Area: Nephrology Product Name: NP-251
Highest Development Status: Preclinical Product Type: Small molecule
Recipient: Algernon Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 23, 2022